Business Wire

MA-ABIOMED

28.4.2021 21:59:07 CEST | Business Wire | Press release

Share
Final Results from the National Cardiogenic Shock Initiative (NCSI) Study Demonstrate the Benefit of Early Cardiac Unloading with Impella

The final results of the physician-led National Cardiogenic Shock Initiative (NCSI) Study demonstrate a 71% survival to discharge with greater than 90% native heart recovery when best practices are used, including placement of an Impella heart pump prior to revascularization (PCI). The study evaluated the outcomes of 406 consecutive patients who presented with acute myocardial infarction cardiogenic shock (AMICS) at 80 participating sites throughout the United States. The study shows a protocol-based approach to increasing survival rates in cardiogenic shock is reproducible in both academic and community hospital settings. Results were presented today by Babar Basir, DO, director of the acute mechanical circulatory support program at Henry Ford Hospital and co-principal investigator of the study, at the 2021 Society of Cardiovascular Angiography & Interventions (SCAI) Scientific Sessions .

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210428006079/en/

The study investigators categorized patients according to SCAI Shock classification stages. For SCAI stages C/D, they found higher survival to discharge (79%), 30-days (77%) and 1-year (62%) compared to historical data in similar patients during the last 30 years. SCAI stage E patients, who are on the brink of cardiovascular collapse, also had improved survival to discharge (54%), 30-days (49%), and 1-year (31%) compared to recent studies of patients who were not treated with the NCSI protocol that published in Journal of American College of Cardiology (33% survival to discharge) and Catherization and Cardiovascular Interventions (22.6% survival to 30-days).

“The NCSI Study demonstrates the benefit of following a protocolized approach to AMICS, which includes early implantation of Impella. We are impressed with the improved survival rates seen with the use of best practices compared to the stagnant historical survival rate,” said Dr. Basir. “It is important to emphasize that the majority of hospitals in the NCSI Study were large community-based programs where heart attack patients first present. Giving these care teams a safe and effective protocol to manage critically ill patients has saved many lives.”

“NCSI is the largest prospective study of therapy for AMICS done in the U.S. in the last 20 years. We have found that the original observations from the Detroit Cardiogenic Shock Initiative have been reproduced showing significantly higher survival rates,” said William O’Neill, MD, medical director of the Henry Ford Health System Center for Structural Heart Disease and co-principal investigator of the study. “If implemented across the country, the NCSI protocol can save 20,000 lives a year.”

Other investigator-led research demonstrates results similar to the NCSI Study results, including the 2019 Inova Study and the 2020 J-PVAD Study . These studies found an 82% and 77% survival at 30 days, respectively, when best practices were followed including the early identification of cardiogenic shock and the early use of Impella. (see figure 1)

“The NCSI Study has shown that, through rapid identification and treatment of patients who will benefit from mechanical circulatory support, higher cardiogenic shock survival rates can be achieved,” said Andrew M. Goldsweig, MD, MS, an assistant professor of interventional cardiology and associate catheterization lab director for structural heart disease at the University of Nebraska Medical Center.

The authors concluded early use of mechanical circulatory support and hemodynamics is associated with improved outcomes. Additional clinical research in the treatment of cardiogenic shock includes the RECOVER IV RCT, which is being developed and will be a prospective, two-arm trial to assess whether Impella pre-PCI is superior to PCI without Impella in AMICS patients. In addition, the DanGer Shock RCT is an ongoing trial in Denmark and Germany assessing primary outcome of death from all causes at six months with Impella CP, compared to standard of care.

To watch Dr. Basir and Dr. O’Neill discuss the NSCI Study results, and the ability of the NCSI protocol to improve outcomes for patients, please visit HeartRecovery.com .

ABOUT IMPELLA HEART PUMPS

The Impella 2.5® and Impella CP® devices are U.S. FDA approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI), such as stenting or balloon angioplasty, to reopen blocked coronary arteries.

The Impella 2.5, Impella CP, Impella CP with SmartAssist®, Impella 5.0®, Impella LD®, and Impella 5.5® with SmartAssist® are U.S. FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.

To learn more about the Impella platform of heart pumps, including their approved indications and important safety and risk information associated with the use of the devices, please visit www.abiomed.com .

ABOUT ABIOMED

Based in Danvers, Massachusetts, USA, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit: www.abiomed.com .

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. Forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ant International's Alipay+ to Connect over 50 Global E-Wallets with Pix of Brazil19.11.2026 09:43:00 CET | Press release

Expanding Alipay+'s national QR scheme connections to 16, spanning Asia, the Middle East and Latin AmericaEnabling international travellers to pay with home wallets at Pix merchants across Brazil, supporting local businesses and inbound tourism Ant International today announced that Alipay+, its global wallet gateway that links over 50 global digital wallets and banking apps, is connected to Pix, Brazil's national instant payment system, expanding cross-border digital payment access for international travellers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119229229/en/ Ant International's global wallet gateway Alipay+ is connecting over 50 e-wallets and banking apps to Pix Powered by Ant International’s AI-native payment and risk management capabilities, the service allows international travellers using their familiar payment apps to scan Pix QR codes at shops, restaurants, and attractions nationwide, without downloadi

Summit Risk Partners Limited Opens for Business as a Registered Lloyd’s Broker Through its Regulated Subsidiaries19.11.2026 09:00:00 CET | Press release

New K2 division launches a modern, data-driven broking house dedicated to the delegated authority sector. Summit Risk Partners Limited (SRP), a newly launched division of K2 Insurance Services, announced today it is officially open for business as a registered Lloyd’s broker. Built specifically for the future of delegated authority, SRP aims to elevate service provision and set a new standard for outcomes across delegated and programme business in the Lloyd’s and London markets. Co-founded by James Baird, CEO, and Jamie Beckett, Managing Director, the specialist broking house operates free from legacy systems and mindsets. SRP combines deep industry expertise with modern technology, actionable insight, and a relentless focus on client success for coverholders, MGAs, underwriting businesses and capacity providers. Key Operational Highlights: Market Status: Registered Lloyd’s broker trading under the pseudonym SUM (Broker Number 2336), sponsored by three leading Lloyd’s Managing Agents.

Man & Science Completes Implantation in ONFIELD First-in-Human Study of Miniaturised ONS System for Chronic Cluster Headache19.11.2026 08:00:00 CET | Press release

Man & Science, a Belgian-based medical device company specialised in miniaturised neurostimulation technologies, today announced that all ten patients have been implanted and activated in its ONFIELD first-in-human pilot study of a miniaturised occipital nerve stimulation (ONS) implant for cluster headache, and that early clinical responses are encouraging. The ONFIELD study is evaluating the safety and feasibility of the Man & Science implant in patients whose cluster headaches remain inadequately controlled despite available treatments. All ten patients planned for this stage of the study have now received the implant and are being followed by the participating clinical team. Early observations show reductions in attack frequency in the patients assessed to date. No serious adverse events related to the implant surgery or the device have been reported so far. A severe and difficult-to-treat neurological disorder Cluster headache is a severe neurological disorder characterised by recu

RSA Compliance Advisor Closes the Governance Gaps Between Audits19.11.2026 07:00:00 CET | Press release

RSA, the identity standard for government agencies, finance, and high-assurance organizations, today announced the general availability of RSA Compliance Advisor, a new capability within RSA® Governance & Lifecycle, the RSA identity governance and administration (IGA) solution, that maps identity governance controls directly to regulatory requirements and reports on compliance posture continuously. Governments and regulators keep raising the bar. GDPR, CJIS, HIPAA, NIST, and POPIA each carry hundreds of requirements, and new regulatory activity keeps adding more. Despite growing regulatory requirements, most compliance programs still confirm their posture the way they did a decade ago: quarterly reviews, annual certifications, manually built spreadsheets. This reactive, periodic assessment doesn’t account for access that changes every day in between. A program built on point-in-time checkpoints can look compliant on the day of the audit and still carry risk that never gets seen. RSA Co

Ant International Launches Whale Orchestration Protocol Under MAS’ BLOOM Initiative to Connect Tokenised Money Market Funds and Tokenised Deposits19.11.2026 07:00:00 CET | Press release

Pilot completed with DBS and Franklin Templeton via Ant’s WhaleRTP platformWhitepaper launched detailing Whale Orchestration Protocol framework and its development under BLOOM Field GuideSolution achieves Singapore’s first successful cross-asset interoperability between tokenised deposits and tokenised money market funds Ant International today announced the launch of the Whale Orchestration Protocol, a major upgrade to its blockchain-based wholesale settlement platform, WhaleRTP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118947513/en/ Developed under the Monetary Authority of Singapore’s (MAS) BLOOM1 (Borderless, Liquid, Open, Online, Multi-currency) initiative, the protocol enables seamless Delivery-versus-Payment (DvP) transactions between tokenised deposits and tokenised money market funds. Through WhaleRTP, the Whale Orchestration Protocol enables secure and atomic settlement between tokenised deposits and token

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye